Fulminant Liver Failure after Treatment with a Checkpoint Inhibitor for Gastric Cancer: A Case Report and Review of the Literature

Fulminant Liver Failure after Treatment with a Checkpoint Inhibitor for Gastric Cancer: A Case Report and Review of the Literature

Nivolumab is a promising monoclonal antibody inhibitor of programmed death-1, a protein on the surface of T-cells. As such, it is approved for use in patients with multiple advanced malignancies and can significantly elongate progression-free survival. However, monoclonal antibody inhibitors can lea...

Full description

Bibliographic Details
Main Authors: Miriam Dibos, Johanna Dumoulin, Carolin Mogler, Silke Wunderlich, Maximilian Reichert, Sebastian Rasch, Roland M. Schmid, Marc Ringelhan, Ursula Ehmer, Tobias Lahmer
Format: Article
Language:English
Published: MDPI AG 2023-07-01
Series:Journal of Clinical Medicine
Subjects:
nivolumab
checkpoint inhibitor
hepatic failure
encephalitis
Online Access:https://www.mdpi.com/2077-0383/12/14/4641

Internet

https://www.mdpi.com/2077-0383/12/14/4641

Similar Items